Rapid symptomatic and radiological response to pembrolizumab–lenvatinib in a 30-year-old man with metastatic sarcomatoid renal cell carcinoma not otherwise specified and extensive osteolytic bone disease
Sarcomatoid dedifferentiation and bone metastases characterize an aggressive subset of metastatic renal cell carcinoma (mRCC) with a poor prognosis. Immune- checkpoint inhibitor combinations are the standard first-line therapy, whilst the role of deferred cytoreductive nephrectomy (dCN) remains debated. We report on th...